<DOC>
	<DOC>NCT00856817</DOC>
	<brief_summary>The purpose of this study is to determine whether heme oxygenase 1 induction by heme arginate treatment is of influence on adenosine induced vasodilation in healthy individuals.</brief_summary>
	<brief_title>Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>at least 18 and no older than 65 on the day of first dosing healthy Quetelet Index (Body Mass Index) of 18 to 30 kg/m2 In general, results of haematology and chemistry should be within the laboratory's reference ranges. Determinants of renal and hepatic function should be within twice the upper limit of normal range. Documented history of sensitivity / idiosyncrasy to medicinal products or excipients history of smoking within the past year history of or current abuse of drugs, alcohol and/or solvents Current use of any (over the counter) medication potentially influencing heme oxygenase or the cardiovascular system Inability to understand the nature and extent of the trial and the procedures required Participation to a drug trial within 60 days prior to the first dose Febrile illness within 3 days before the first dose Heterozygosity (LS) or homozygosity (LL) with regard to the number of GT repeats in the HO1 promoter region</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>